Does Geron Corporation Stock Belong in Your Portfolio in 2020?
Geron Corporation (NASDAQ: GERN) is a prototypical jackpot stock candidate. For those of you new to this concept, jackpot stocks are equities that sport dirt-cheap valuations -- relative to their long-term growth potential -- due to their exceedingly high risk profiles. In a nutshell, these types of stocks can, on occasion, produce life-changing returns on capital. But they also come with the inherent risk of losing most -- if not all -- of your capital.
Geron fits this profile to a tee. After Johnson & Johnson's (NYSE: JNJ) biotech subsidiary Janssen handed back the commercial rights to the blood cancer drug candidate imetelstat in late 2018, Geron was immediately tasked with advancing the drug's ongoing clinical program. The bright side is that imetelstat was showing promise as an important advancement in the treatment of a rare blood cancer known as myelodysplastic syndromes (MDS) at the time J&J decided to end the partnership. Moreover, imetelstat's midstage trial for intermediate-2 or high-risk myelofibrosis (MF) was yielding some encouraging trends as well.
Image source: Getty Images.
Source Fool.com
